ibrutinib capsules

Ibrutinib(Ibrutinib)is suitable for the treatment of the following diseases; chronic lymphocytic leukemia(CLL)/small lymphocytic lymphoma(SLL); in the United States, it is used in adult patients with or without 17p deletion; in Europe and Canada, it is used as a single agent or in combination with rituximab, obinutuzumab, or venetoclaxin patients with previously untreated CLL. Bendamustine may be used alone or in combination with bendamustine and rituximab for Waldenstrom's macroglobulinemia and for chronic graft-versus-host disease in patients who have received at least one previous therapy. In the United States, it is approved for use in patients one year of age or older after failure of one or more systemic therapies. In Canada, it is approved for use in adults with steroid-dependent or refractory cGVHD. In Europe and Canada, ibrutinib is also used to treat adults with relapsed or refractory MCL. In Canada, it is approved for use in adults who require systemic therapy and have received at least one prior antiCD20 therapy. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to learn more about high-quality overseas drugs for you.